Vertex Pharmaceuticals, Inc.

Some of the best links we picked up around the internet

CMN Weekly (2 August 2024) - Your Weekly CRISPR...

CMN Weekly

Aug. 2, 2024

Some of the best links we picked up around the internet

CMN Weekly (21 June 2024) - Your Weekly CRISPR...

CMN Weekly

Jun. 21, 2024

Some of the best links we picked up around the internet

CMN Weekly (14 June 2024) - Your Weekly CRISPR...

CMN Weekly

Jun. 14, 2024

Some of the best links we picked up around the internet

CMN Weekly (10 May 2024) - Your Weekly CRISPR...

CMN Weekly

May. 10, 2024

Some of the best links we picked up around the internet

CMN Weekly (19 January 2024) - Your Weekly CRISPR...

CMN Weekly

Jan. 19, 2024

Some of the best links we picked up around the internet

Clinical Highlights From the Gene-Editing Field in...

CMN Clinical

Dec. 29, 2023

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

CMN Weekly (15 December 2023) - Your Weekly CRISPR...

CMN Weekly

Dec. 15, 2023

Some of the best links we picked up around the internet

Vertex Pharmaceuticals, Inc.

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle cell disease, SCD, (NCT05951205)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04208529)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05356195)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III